We would like to share updates regarding preauthorization under our Utilization Management (UM) Program.  

Our commitment to assisting members and providers through the many challenges faced during case surges and hospitalizations guided our business decision to continue the cost-share waiver for COVID-19 treatment for our fully insured members. Some of our self-funded groups also chose to extend the member cost-share waiver. 

Jubilant Cadista Pharmaceuticals Inc. is conducting a market recall at the wholesale level all quantities of all unexpired lots Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets, USP distributed under the Cadista label due to the presence of azido, a potential mutagenic impurity. Azido is considered a mutagen, which is a chemical substance that can cause a change in the DNA of a cell. These mutations may increase the risk of cancer, but the specific risk for this azido impurity to cause cancer in humans is unknown.